Although targeting cancer metabolism is a promising therapeutic strategy, clinical success will depend on an accurate diagnostic identification of tumor subtypes with specific metabolic requirements. Through broad metabolite profiling, we successfully identified three highly distinct metabolic subtypes in pancreatic ductal adenocarcinoma (PDAC). One subtype was defined by reduced proliferative capacity, whereas the other two subtypes (glycolytic and lipogenic) showed distinct metabolite levels associated with glycolysis, lipogenesis, and redox pathways, confirmed at the transcriptional level. The glycolytic and lipogenic subtypes showed striking differences in glucose and glutamine utilization, as well as mitochondrial function, and corresponded to differences in cell sensitivity to inhibitors of glycolysis, glutamine metabolism, lipid synthesis, and redox balance. In PDAC clinical samples, the lipogenic subtype associated with the epithelial (classical) subtype, whereas the glycolytic subtype strongly associated with the mesenchymal (QM-PDA) subtype, suggesting functional relevance in disease progression. Pharmacogenomic screening of an additional ∼200 non-PDAC cell lines validated the association between mesenchymal status and metabolic drug response in other tumor indications. Our findings highlight the utility of broad metabolite profiling to predict sensitivity of tumors to a variety of metabolic inhibitors.
Although targeting cancer metabolism is a promising therapeutic strategy, clinical success will depend on an accurate diagnostic identification of tumor subtypes with specific metabolic requirements. Through broad metabolite profiling, we successfully identified three highly distinct metabolic subtypes in pancreatic ductal adenocarcinoma (PDAC). One subtype was defined by reduced proliferative capacity, whereas the other two subtypes (glycolytic and lipogenic) showed distinct metabolite levels associated with glycolysis, lipogenesis, and redox pathways, confirmed at the transcriptional level.
The glycolytic and lipogenic subtypes showed striking differences in glucose and glutamine utilization, as well as mitochondrial function, and corresponded to differences in cell sensitivity to inhibitors of glycolysis, glutamine metabolism, lipid synthesis, and redox balance.
In PDAC clinical samples, the lipogenic subtype associated with the epithelial (classical) subtype, whereas the glycolytic subtype strongly associated with the mesenchymal (QM-PDA) subtype, suggesting functional relevance in disease progression. Pharmacogenomic screening of an additional ∼200 non-PDAC cell lines validated the association between mesenchymal status and metabolic drug response in other tumor indications. Our findings highlight the utility of broad metabolite profiling to predict sensitivity of tumors to a variety of metabolic inhibitors.
metabolite profiling | metabolic subtypes in PDAC | glycolysis | lipid synthesis | biomarkers for metabolic inhibitors M etabolic reprogramming during tumorigenesis is an essential process in nearly all cancer cells. Tumors share a common phenotype of uncontrolled cell proliferation and must efficiently generate the energy and macromolecules required for cellular growth. The first example of metabolic reprogramming was discovered more than 80 y ago by Otto Warburg: tumor cells can shift from oxidative to fermentative metabolism in the course of oncogenesis (1). More recently, there has been a resurgence of interest in targeting cancer metabolism (2-4) because it may not only be effective in inhibiting tumor growth, but may also provide a therapeutic window (5, 6) . For example, inactivation of lactate dehydrogenase-A (LDHA), an enzyme that catalyzes the final step of aerobic glycolysis, thereby reducing pyruvate to lactate, decreases tumorigenesis and induces regression of established tumors in mouse models of lung cancer driven by oncogenic KRAS or epidermal growth factor receptor (EGFR) while minimally affecting normal cell function (7) . The finding that cancers have altered metabolism has prompted substantial investigation, both preclinically and in clinical trials, of several metabolically targeted agents, including those that elevate reactive oxygen species (ROS) or block glycolysis, lipid synthesis, mitochondrial function, and glutamine synthesis pathways (8) .
The identification of distinct metabolic reprogramming events or metabolic subtypes in cancer may inform patient selection for investigational metabolic inhibitors and in the selection of new therapeutic targets (9, 10) . Just as tumors vary greatly in genomic alterations that impact signaling and regulatory pathways, metabolic transformation is also heterogeneous and dependent on tissue type, proliferation rate, and isoenzyme use (9, 11) . In addition, the observed differences in the dependence on and utilization of the major nutrients-glutamine and glucose-are linked to oncogenic signaling and the genomic features of a cancer cell (12) .
Large-scale pharmacogenomic screening is a powerful method for identifying biomarkers of drug response and can accelerate the search for new cancer therapies (13, 14) . In this study, we used broad baseline metabolite profiling in cell line models of pancreatic ductal adenocarcinoma (PDAC), a disease context previously associated with altered metabolism (15) (16) (17) (18) , to identify metabolic subtypes within PDAC and predict their sensitivity to various metabolic inhibitors.
Results
Baseline Metabolite Profiling Identifies Three Metabolic Subtypes in PDAC. We examined cell lines derived from naturally occurring tumors because they recapitulate many aspects of the tissue type
Significance
Targeting cancer metabolism requires personalized diagnostics for clinical success. Pancreatic ductal adenocarcinoma (PDAC) is characterized by metabolism addiction. To identify metabolic dependencies within PDAC, we conducted broad metabolite profiling and identified three subtypes that showed distinct metabolite profiles associated with glycolysis, lipogenesis, and redox pathways. Importantly, these profiles significantly correlated with enriched sensitivity to a variety of metabolic inhibitors including inhibitors targeting glycolysis, glutaminolysis, lipogenesis, and redox balance. In primary PDAC tumor samples, the lipid subtype was strongly associated with an epithelial phenotype, whereas the glycolytic subtype was strongly associated with a mesenchymal phenotype, suggesting functional relevance in disease progression. Our findings will provide valuable predictive utility for a number of metabolic inhibitors currently undergoing phase I testing.
and genomic context of cancer (13, 14, 19, 20) . Levels of 256 metabolites were quantified in 38 pancreatic cancer cell lines (five biological replicates per cell line) in logarithmic growth phase using media with physiological glucose and glutamine concentrations (Datasets S1-S3). We applied nonnegative matrix factorization (NMF) (21), a recently established approach for consensus clustering (22) (23) (24) , to 153 metabolites with reproducible variation, allowing the capture of the strongest signal of metabolic dependency (SI Materials and Methods). This analysis revealed three stable and reproducible subtypes with adequate data coherence ( Fig. S1 A and B) . The metabolite profiles of the cell lines ordered by subtype are shown in Fig. 1A for metabolites with distinct intensities in at least one subtype compared with the other two subtypes (F test, P < 0.05). These three subtypes provided a useful and interpretable basis for further analysis.
Metabolic Characterization Reveals a Slow Proliferating, Glycolytic, and Lipogenic Subtype. The metabolite intensities within each subtype were then mapped to known, previously established metabolic ontologies (Dataset S1 and SI Materials and Methods) (25) . One subtype (34% of all lines) was especially low in amino acids and carbohydrates (Fig. 1A , left subtype, and Fig. S1C ). Cell lines in this subtype had an average doubling time that was significantly higher (Fig. S1D ) and were named the slow proliferating subtype. Doubling times for cell lines from the other two subtypes were more similar (Fig. S1D) ; however, these two subtypes displayed strikingly distinct metabolic profiles, independent of proliferation rate (SI Materials and Methods). Thus, these metabolic subtypes have unique metabolic profiles that are independent of growth rate.
We further explored the metabolic differences between the two subtypes with similar proliferation rates. One subtype (27% of all lines; Fig. 1A ) exhibited, on average, elevated levels of various components of the glycolytic and serine pathways, mainly phosphoenolpyruvate (PEP), glyceraldehyde-3-phosphate, lactate, and serine ( Fig. 1 B and C and Fig. S1E ), and was named the glycolytic subtype. This subtype was also distinguished by lower levels of metabolites important for redox potential such as nicotinamide adenine dinucleotide (NAD) reduced (NADH), NAD phosphate (NADP), NAD phosphate reduced (NADPH), glutathione disulfide (GSSG), glutathione (GSH), and flavine adenine dinucleotide ( Fig. 1 B and C, Fig. S1F , and Dataset S4). In contrast, the other subtype (39% of all lines; Fig. 1A Transcriptionally. We next determined whether differences in metabolite levels observed between the glycolytic and lipogenic subtypes could be explained by differences in the expression of genes known to be associated with the metabolic ontologies (Dataset S5 and SI Materials and Methods). Consistent with the differences in metabolite levels, expression of genes associated with glycolysis and the pentose phosphate pathway were found to be relatively elevated in cell lines from the glycolytic subtype ( Fig. 1 E and F, Fig.  S1 H and I, and Dataset S6). For example, most glycolytic lines demonstrated higher expression of neuron-specific enolase [ENO2; adjusted P = 0.0016; Fig. 1 E and F] , along with higher levels of its product PEP, whereas other enolase homologs were not differentially expressed (Fig. S1J) . We also noted that protein (and not mRNA) abundance of the lactate transporter, monocarboxylate transporter 1 (MCT1) was elevated in the glycolytic lines compared with the lipogenic lines (P < 0.05; Fig. 1E and Fig. S1K ). In contrast, cell lines within the lipogenic subtype were enriched for expression of lipogenesis genes involved in cholesterol and de novo lipid synthesis including 7-dehydrocholesterol reductase (DHCR7), stearoyl-CoA desaturase (SCD), and fatty acid synthase (FASN) (adjusted P < 0.1; Fig. 1 E and F, Fig. S1 H and L, and Dataset S6). Thus, PDAC-derived cell lines can be clustered by their metabolite profiles and these differences appear to be determined in part by differences in gene expression.
Glycolytic and Lipogenic Subtypes Use Glucose and Glutamine in a Different Manner. The metabolic and transcriptional profiles suggested that these two subtypes may differ in their use of glucose and glutamine, the most abundant carbon sources available to cancer cells. We predicted that the lipogenic subtype would preferentially use glucose for the tricarboxylic acid (TCA) cycle and lipid synthesis, whereas the glycolytic subtype would use glucose more for aerobic glycolysis, and consequently, use more glutamine for TCA anaplerosis. C-glucose into lipid metabolites at a significantly higher level than cell lines from the glycolytic subtype ( Fig. 2C ; P < 0.01). Consistent with these observations, lipogenic lines showed on average higher O 2 consumption ( Fig. 2D ; P < 0.01) and a greater mitochondrial content [Mitotracker and tetramethylrhodamine ethyl ester (TMRE) intensity] compared with glycolytic subtype lines ( Fig. 2E ; P < 0.01; Dataset S7). Thus, cell lines from the glycolytic and lipogenic subtypes appear to use glucose and glutamine in a different manner.
Glycolytic and Lipogenic Cell Lines Show Distinct Sensitivity to
Various Metabolic Inhibitors in Vitro. Based on their distinct metabolic wiring, we predicted that glycolytic and lipogenic cell lines would show differential sensitivity to inhibitors targeting aerobic glycolysis (oxamate and the LDHA inhibitor GNE-140) (26), glutaminolysis [bis-2-(5-phenylacetimido-1,2,4,thiadiazol-2-yl)ethyl sulfide (BPTES)], and de novo lipid synthesis [FASN inhibitor GSK1195010 (27) , SCD inhibitor (28), cerulenin, and orlistat]. Indeed, as predicted, the glycolytic subtype was enriched for lines that were sensitive to the LDHA inhibitor, oxamate, and BPTES, whereas the lipogenic subtype was enriched for lines that were sensitive to inhibitors targeting lipid synthesis ( Fig. 3A and Fig.  S2A ; P < 0.05; Dataset S7 and SI Materials and Methods). Moreover, glycolytic cell lines showed higher rates of fatty acid (FA) uptake ( Fig. S2B) and increased sensitivity to media with reduced lipid content (Fig. S2C ), suggesting these lines may be more reliant on FA pathways for generating lipids.
Maintaining redox balance is another key requirement for cancer cells (29) . The differences in redox-related metabolites between glycolytic and lipogenic cell lines suggested that they may also show differential sensitivity to ROS-inducing agents or inhibitors of enzymes or transporters important for maintaining glutathione synthesis and NADP/NADPH balance in cells. Indeed, we found that cell lines within the glycolytic subtype showed enhanced sensitivity to a variety of such agents including inhibitors of gamma-glutamylcysteine synthetase [buthionine sulphoximine (BSO)], and the cystine transporter xCT {(S)-4-carboxyphenylglycine [(S)-4-CPG]} (Fig. 3B and Dataset S7).
In addition to short-term (3 d) culture assays, we tested the efficacy profile of LDHA inhibitor, oxamate, and the SCD inhibitor in long-term (12 d) culture assays and observed similar results (Fig. 3 A and C) . Normalized metabolite intensity levels for metabolites involved in lipid synthesis that were differentially expressed between glycolytic and lipogenic lines. (E) Detailed metabolite map with genes differentially expressed between cell lines from the glycolytic vs. lipogenic subtype indicated with various shades of color depending on P value corrected for multiple testing. For MCT1, P value is based on protein expression level. We refer to Dataset S6 for a list of differentially expressed genes. (F) Expression levels of ENO2, DHCR7, SCD, and FASN involved in glycolysis and lipid synthesis that were differentially expressed between glycolytic and lipogenic lines (Dataset S6). Asterisks denote a statistically significant difference by unpaired t test with Welch's correction (*P < 0.05, **P < 0.01, ***P < 0.001).
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Functional Confirmation of the Glycolytic and Lipogenic Subtype in
Vivo. To translate these findings in vivo and generate proof-ofconcept findings for our two metabolic subtypes, we evaluated xenografts of MIA Paca-2, a glycolytic cell line, and HPAC, a lipogenic cell line, for their sensitivity to glycolysis vs. lipid synthesis inhibition. Because oxamate and LDHA inhibitors have poor pharmacokinetics in mice (26), we inhibited glycolysis by engineering MIA Paca-2 and HPAC cells to express a doxycline (DOX)-inducible shRNA against LDHA. MIA Paca-2 xenograft tumors treated with DOX showed undetectable levels of LDHA (Fig. 3D ) and 68% tumor growth inhibition (TGI) compared with tumors expressing LDHA (Fig. 3E) . In contrast, administration of an SCD inhibitor showed no efficacy (Fig. 3E) , although pharmacodynamic inhibition of SCD was seen (Fig. 3F) . In contrast, HPAC xenograft tumors showed minimal sensitivity to LDHA knockdown (9% TGI; Fig. S2 D and E) but showed significant tumor growth inhibition to SCD inhibitor treatment (52% TGI) (30) . Thus, glycolytic and lipogenic subtypes are functionally distinct and show differential sensitivity to glycolytic and lipid biosynthesis inhibition.
Glycolytic and Lipogenic Subtypes Are Associated with Known
Subtypes of PDAC, Driven by Mesenchymal Status. We next set out to determine how our defined metabolic subtypes associated A-E, the mean and SD between cell lines belonging to the glycolytic subtype vs. lipogenic subtype is plotted where each cell line is shown as one dot, representing the mean of three replicates. Data are normalized to sample protein content (A-C) or cell number (D and E). Asterisks denote a statistically significant difference by unpaired t test with Welch's correction (*P < 0.05, **P < 0.01, ***P < 0.001).
with primary PDAC tumor samples from patients. Three clinical subtypes of PDAC were recently identified through molecular profiling of PDAC tumors: classical (characterized by high expression of adhesion-associated and epithelial genes), quasi-mesenchymal (QM-PDA, characterized by mesenchyme-associated genes), and exocrine-like (22) . Because exocrine-like cell lines have not been reported, we simplified the three-subtype PDAC signature to a 42-gene expression signature that distinguishes classical from QM-PDA (22) , and applied it to our cell line panel. We found that all cell lines within the glycolytic subtype associated with the quasimesenchymal subtype, whereas most lipogenic lines were associated with the classical subtype ( Fig. 4A ; P = 0.0006; Dataset S7). Thus, our metabolite subtypes derived from pancreatic cell lines strongly correlate with known subtypes of PDAC tumors, with the glycolytic subtype strongly associating with mesenchymal features and the lipogenic subtype associating with epithelial features. 22, 31, 32) . Given the strong association between quasi-mesenchymal status and glycolytic dependency in the PDAC lines, we asked whether this association might also exist in other tumor types. We screened ∼200 nonpancreatic cancer cell lines, representing various tumor types, for sensitivity to inhibitors of aerobic glycolysis and glutaminolysis, as well as to ROS-inducing agents (Dataset S8). As in PDAC (Fig. 1E and Fig. S1H ), we found that cell lines most sensitive to the LDHA inhibitor, oxamate, and BPTES were associated with a glycolytic signature, whereas cell lines that were most resistant to these inhibitors were associated with an OXPHOS signature ( Fig. 4B and Fig. S3A ). We next assigned each cell line to a metabolic subtype (glycolytic vs. lipogenic) using the glycolytic and lipid genes that were most differentially expressed in the PDAC metabolic subtypes (adjusted P < 0.05). Using the ratio of expression of glycolytic gene ENO2 to the average expression of lipid genes diacylglycerol O-acyltransferase 1 (DGAT1), DHCR7, farnesyl-diphosphate farnesyltransferase 1 (FDFT1), 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), and mevalonate (diphospho) decarboxylase (MVD) clearly distinguished nonpancreatic cell lines by metabolic dependency preference (Fig. 4C) . A glycolytic preference in nonpancreatic lines associated with sensitivity to LDHA inhibitor, oxamate, and BPTES ( Fig. S3 D and E) . Thus, mesenchymal tumors, regardless of indication, appear to share common metabolic vulnerabilities, and agents that block glycolysis, glutamine metabolism, or redox balance may be particularly effective. These results support a model in which metabolic plasticity with regard to bioenergetic pathways is limited, and, consequently, unique metabolic dependencies exist in tumors that can be exploited for cancer therapy based on tumor subtype.
Discussion
Using broad metabolite profiling, we successfully stratified PDAC-derived cell lines into discrete metabolic subtypes. Previous metabolic profiling studies have been conducted in tumors and in cell lines of the NCI-60 panel with different end points (9) . However, this study is the first, to our knowledge, to successfully identify metabolic subtypes through profiling of a large number of samples within one tissue type and to demonstrate that each subtype is enriched for drug sensitivity to unique classes of metabolic inhibitors. Although metabolic clustering accounted for a substantial fraction of the drug response variation observed across cancer cell lines, some heterogeneity in drug response within the lipogenic subtype remained (see SI Text and Figs. S4 and S5 for a discussion on heterogeneity). Some cell lines were clearly "hard-wired" for lipogenesis and showed sensitivity to all lipid inhibitors tested, whereas the more refractory lines appeared to be capable of switching to alternative pathways, perhaps those involving fatty acid uptake. Further understanding of the nature and plasticity of metabolic networks in these cancer cells will be required to more accurately predict their sensitivity to specific classes of metabolic inhibitors. In addition, although we successfully translated our in vitro findings in vivo, additional factors within the tumor microenvironment (tumor-stroma signaling, angiogenesis, and hypoxia) will influence sensitivity and adaptation to metabolic inhibition in vivo.
Our study also identified PEP as one of the most differentially expressed metabolites between glycolytic and lipogenic cell lines.
ENO2, which converts 2-phosphoglycerate (2-PG) to PEP, was also one of the most differentially expressed genes between these two subtypes, suggesting that inhibitors of ENO2 may be particularly effective against glycolytic tumors. Enolases act downstream of phosphoglycerate mutase (PGAM1) and regulate pyruvate kinase (PK) M2 isoform (PKM2), genes that are particularly active in glycolytic tumors and have recently attracted attention for their role in serine biosynthesis through regulation of 3-phosphoglycerate dehydrogenase (PHGDH) (34) . ENO2 has also been proposed as a target in ENO1-deleted glioblastomas (35) . Our findings further substantiate the biological rationale for targeting ENO2 in a subset of cancers.
Finally, we demonstrated that the observed metabolic subtypes correlate with epithelial vs. (quasi)-mesenchymal cell states both in PDAC and other cancer types. We propose a model (Fig.  4F ) in which mesenchymal tumors are metabolically wired to preferentially use glucose for glycolysis and lactate production and use glutamine for generating TCA metabolites, whereas epithelial tumors preferentially use glucose for the TCA cycle and de novo lipogenesis. Moreover, our analysis suggests that mesenchymal tumors may be more vulnerable to ROS-inducing agents, potentially through differences in NADPH balance and antioxidant responses (36) .
Such differences in metabolic vulnerabilities between epithelial and mesenchymal states could arise from the activation of signaling pathways associated with these states. For example, epithelial subtypes have previously been shown to be enriched for activating mutations in receptor tyrosine kinases (RTK) such as EGFR (37) and PI3K/AKT signaling pathways (23), leading to activation of the mechanistic target of rapamycin (mTOR). mTOR increases both protein synthesis and lipogenesis through mechanisms including enzyme phosphorylation and transcriptional activation of EIF1A (38) and SREBP1 (39-41). In contrast, mesenchymal states are associated with increased c-Myc expression and HIF1A, which have been shown to drive a glycolytic profile (42, 43) . Regardless of the nature or mechanism of action for the metabolic variation we observed, our data provide valuable predictive utility and thereby inform clinical evaluation of a variety of metabolic inhibitors such as MCT and glutaminase inhibitors currently undergoing phase I testing across a variety of tumor indications.
Materials and Methods
Detailed materials and methods can be found in SI Materials and Methods. All cell lines listed in Dataset S9 were grown in RPMI (without glucose, without glutamine) media (US Biological #R9011) supplemented with 6 mM glucose, 2 mM glutamine, 5% FBS, 100 μg/mL penicillin, and 100 U/mL streptomycin. Metabolite profiling was performed as previously described (44). For flux analysis, cells were cultured for ∼18 h in RPMI with 10% (vol/vol) dialyzed FBS supplemented with either 3 mM D[U- 13 C]glucose or 1 mM L[U-13 C]glutamine. Data analysis was carried out with the MultiQuant software. For short-term viability assays, cells were plated using optimal seeding densities in 384-well plates. The following day, cells were treated with LDHA inhibitor GNE-140 (26), oxamate (Sigma cat# O2751), SCD inhibitor (28), FASN inhibitor GSK1195010 (27) , cerulenin, orlistat, BSO, S-4-CPG, aminooxyacetic acid (AOA), and BPTES (45), using a 6-pt dose titration scheme. After 72 h, cell viability was assessed using the CellTiter-Glo Luminescence Cell Viability assay. Absolute inhibitory concentration (IC) values were calculated using four-parameter logistic curve fitting and are averages from a minimum of two independent experiments. For long-term growth assays, glycolytic cell lines (MIA Paca-2, SW 1990, PSN1, and HUP-T3) and lipogenic cell lines (PA-TU-8902, PK-8, KP-3L, and SUIT-2) were seeded in a 6-well dish at 3,000 cells per well overnight (RPMI, 5% serum, 2 mM glutamine) and then treated in media with indicated concentrations of oxamate, SCD inhibitor, or DMSO for 12 d at 37°C and 5% CO 2 . Fatty uptake assays were performed using the Free Fatty Acid Uptake Assay Kit (ab176768) according to the manufacturer's protocol. Reduced serum experiments were carried out using 3% delipidated serum (SeraCare 502099) and 1% FBS (SeraCare CC5010-500). Seahorse Bioscience assays were used for oxygen consumption. All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Genentech and carried out in an AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care) accredited facility. All statistical analyses were performed in R 3.0.0 (46) . The optimal number of metabolic subtypes was obtained with nonnegative matrix factorization, using the NMF package. The DESeq2 package was used for differential expression analysis. Metabolic ontology and gene set enrichment analyses were based on GSEAlm.
ACKNOWLEDGMENTS. We thank Richard Bourgon, Eva Lin, Billy Lam, Yihong Yu, and Arjan Gower for help with cell-based drug screens and data analysis, Mandy Kwong for advice on 13 C metabolic mass isotopomer distribution analysis (MIDA), Allison Bruce for assistance with the metabolic diagram, and Metanomics Health (Lisette Leonhardt, Ulrike Rennefarhrt, Oliver Schmitz, and Hajo Schiewe) for technical support on metabolite profiling.
